Impact
Report 2025
Advancing Health for Society
Find.
Build.
Scale.
In a healthcare landscape challenged by market complexities, regulatory barriers, and industry fragmentation, only 5% of healthtech inventions ever reach the patients they were designed to help. NLC is changing this by finding, building, and scaling transformative health technologies.
We identify high-impact innovations, develop them into market-ready ventures, and ensure they reach the patients and professionals who need them most. As healthcare systems face rising costs, aging populations, and increasing chronic diseases, innovation is more crucial than ever.
By collaborating with leading institutions, corporations, and medical experts, we turn groundbreaking ideas into life-changing solutions that improve healthcare worldwide.
A word by our CEO
"A resilient society starts with a healthy one. When healthcare systems struggle, the impact reaches far beyond hospitals, touching families, communities, and entire economies.
At NLC, we turn breakthrough science into solutions that strengthen healthcare systems and create lasting societal value.
The future of healthcare won’t build itself—let’s build it together."
.jpg)
This year’s numbers
In 2025, we sharepened our focus, backing high potential ventures, evaluating breakthrough technologies, and securing critical funding to accelerate healthcare innovation.
Patients impacted
Our ventures are already delivering meaningful impact for patients. In 2025, companies across our portfolio reached more than 72,000 patients. As more ventures advance toward commercialization and bring their innovations to market, this impact will continue to grow.
Measuring our impact
The actions of NLC lead to the creation of portfolio companies which have the potential to solve the world’s healthcare challenges, with society serving as the foundational theme for this year's report.
Happy Society
Our ventures create lasting value for society by making healthcare more accessible and affordable. Across our portfolio, 100% of ventures expect to deliver positive societal impact, with 94% aiming to reduce healthcare costs, 84% to reduce overall FTE requirements, and 90% to ease caregiver burdens.
Happy Patients
Our ventures improve patient wellbeing by enabling faster diagnoses, improved treatment outcomes, and better healthcare experiences. Across our portfolio, 100% of ventures anticipate a positive patient impact, with 90% expected to reduce emotional burden, 89% to alleviate pain and discomfort, and 78% to increase life expectancy.
Happy Workforce
Our ventures support healthcare professionals by reducing administrative and physical burdens and helping create safer, more sustainable work environments. Across our portfolio, 79% of ventures expect to make a positive impact on the healthcare workforce.
Happy Planet
Our ventures reduce healthcare's environmental footprint by improving care efficiency and lowering energy consumption and waste. Across our portfolio, 57% of ventures expect to make a positive environmental impact compared with current standards of care, and 41% indicate a neutral footprint.
2025 at a glance: Happy Society
Healthcare systems face growing financial and operational pressure. Aging populations and the rise of chronic disease are increasing demand for care, while shortages of healthcare professionals and persistent system inefficiencies place additional strain on already stretched services.
Our ventures address this challenge by developing solutions that optimize treatment pathways, support earlier recovery, and make better use of clinical expertise—helping reduce the total cost of care while expanding healthcare system capacity.
.jpg)
Venture spotlight
With 66 active ventures, our portfolio is driving innovation in healthcare and creating lasting impact for patients and society.
“We strive to make prostate cancer diagnosis quicker, more affordable, and less invasive by pairing artificial intelligence technology with ultrasound imaging.”
Mark Bloemendaal
CEO, PCaVision
“Addressing bacterial infections and the growing threat of antimicrobial resistance is one of the most significant societal challenges ahead. The World Health Organisation has called it ‘the next pandemic’, and as populations age, the problem will only accelerate. Our technology directly confronts this challenge.”
Richard van de Wateringen
CEO, IPD
“Ultimately, our work could reduce the long-term healthcare burden and improve independence for patients with CMT2D and related neuromuscular conditions, offering hope where current therapies fall short.”
Dr. Erik Storkebaum
Inventor, tRNA Bio
Steven Coughlin
CEO, Respiosa
Read all details in the full report